Lé Ana Maria, Gooderham Melinda, Torres Tiago
Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, 4000-001, Portugal.
SkiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, ON, K9J 5K2, Canada.
Immunotherapy. 2023 Nov;15(16):1351-1362. doi: 10.2217/imt-2023-0057. Epub 2023 Sep 5.
Abrocitinib is an oral small molecule which selectively inhibits JAK1, modulating multiple cytokine pathways involved in atopic dermatitis. Both abrocitinib 200 mg and 100 mg reached efficacy results comparable to dupilumab and superior to placebo. Abrocitinib 200 mg was superior to dupilumab in some trials, consistently providing a faster response and itch relief from week 2 to 26. Continuous abrocitinib 200 mg is the most effective at controlling this disease, but with an induction-maintenance approach with abrocitinib 200 mg followed by 100 mg, over 55% of patients did not flare for 40 weeks. Abrocitinib common adverse effects are nonserious. A self-limited dose-related decrease in platelet counts was consistently observed, without clinical repercussion. Abrocitinib demonstrated high efficacy and a favorable safety profile.
阿布昔替尼是一种口服小分子药物，可选择性抑制JAK1，调节参与特应性皮炎的多种细胞因子途径。阿布昔替尼200毫克和100毫克的疗效结果与度普利尤单抗相当，且优于安慰剂。在一些试验中，阿布昔替尼200毫克优于度普利尤单抗，从第2周到第26周始终能更快地缓解症状和减轻瘙痒。持续服用200毫克阿布昔替尼对控制该病最有效，但采用先服用200毫克阿布昔替尼然后服用100毫克的诱导-维持疗法，超过55%的患者在40周内未出现病情复发。阿布昔替尼的常见不良反应并不严重。持续观察到血小板计数有与剂量相关的自限性下降，但无临床影响。阿布昔替尼显示出高效性和良好的安全性。
